Genelux (GNLX) Non Operating Investment Income (2024 - 2026)
Genelux (GNLX) recorded quarterly Non Operating Investment Income of -$14000.0 in Q1 2026, down 1500.0% quarter-over-quarter from $1000.0 in Q4 2025, and up 60.0% on a YoY basis from -$8750.0 in Q1 2025.
Genelux (GNLX) Non Operating Investment Income (2024 - 2026) Analysis & Trends
Genelux's Non Operating Investment Income history runs 3 years deep, the most recent figure standing at -$14000.0 for Q1 2026.
- In Q1 2026, Non Operating Investment Income rose 60.0% year-over-year to -$14000.0; the TTM figure through Mar 2026 stood at -$34000.0 (down 200.0% YoY), while the FY2025 annual figure was -$55000.0, down 210.0% from the prior year.
- Non Operating Investment Income was -$14000.0 for Q1 2026 at Genelux, down from $1000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $135000.0 in Q3 2024 to a low of -$60000.0 in Q4 2024.
- Historically, Non Operating Investment Income has averaged -$2111.1 across 3 years, with a median of -$14000.0 in 2026.
- Biggest YoY gain for Non Operating Investment Income was 101.67% in 2025; the steepest drop was 333.33% in 2025.
- A 3-year view of Non Operating Investment Income shows it stood at -$60000.0 in 2024, then surged by 101.67% to $1000.0 in 2025, then tumbled by 1500.0% to -$14000.0 in 2026.
- The last three Non Operating Investment Income figures came in at -$14000.0 (Q1 2026), $1000.0 (Q4 2025), and $5000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 230,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | -14,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14,000.00 |
| Mar 31, 2026 | -14,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Sep 30, 2025 | 5,000.00 |
| Jun 30, 2025 | -26,000.00 |
| Jun 30, 2025 | -26,000.00 |
| Mar 31, 2025 | -35,000.00 |
| Mar 31, 2025 | -35,000.00 |
| Dec 31, 2024 | -60,000.00 |
| Dec 31, 2024 | -60,000.00 |
| Sep 30, 2024 | 135,000.00 |
| Sep 30, 2024 | 135,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Jun 30, 2024 | -6,000.00 |
| Mar 31, 2024 | -19,000.00 |
| Mar 31, 2024 | -19,000.00 |